Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (March 2025)
26 slides from Pluri's investor presentation, March 2025
Slide 1: Where Technology Comes to Life
WHERE TECHNOLOGY COMES TO LIFE Q1 2025
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Pluri Venture Creation
Pluri Venture Creation Company Sectors Partners Regenerative Medicine ~$22 million (as of December 31, 2024) Cultivated Meat ~ Contract Development and Manufacturing Organization Cell-Based Agriculture
Slide 4: From Single Cells To Sustainable Solutions
From Single Cells To Sustainable Solutions Pluri harnesses the power of cells, the building blocks of life, to deliver eco-friendly solutions that aim to enhance individual well-being and drive positive global change
Slide 5: Eight Billion Lives. One Planet. Zero Time to Waste.
Eight Billion Lives. One Planet. Zero Time to Waste. Aging and Health Climate Change Food Security Sustainability A growing, aging world urgently needs scalable, sustainable solutions
Slide 6: Pluri Technological Platform
Pluri Technological Platform Innovative Validated
Slide 7: PluriMatrix Industrial Scale Production
PluriMatrix™ Industrial Scale Production
Slide 8: Over Two Decades of Leadership with Cell-based Solutions
Over Two Decades of Leadership with Cell-based Solutions Pluri leverages its expertise and proprietary platform for cell-based solutions to create a collaborative network of ventures and partnerships
Slide 9: Cell-based Technology Platform
Cultivated cacao Immunotherapy AgTech Acute Radiation Osteoarthritis Cell-based Cultivated CDMO Technology Platform Coffee Cultivated Meat And beyond A collaborative network of companies Knowhow Validated Deep market Infrastructure GMP facility and expertise technology understanding and and corporat
Slide 10: A Clear Path to Venture Creation
A Clear Path to Venture Creation Feasibility & de-risking Model options Ventures Coffeesai 1. Ideation and market Company Creation assessment Pluri CDMO 2. Partner collaboration for need validation Ever After Foods 3. Team recruitment Joint-Venture PROTO 4. POC Funding and validation 5. Corporate de
Slide 11: A Clear Path to Venture Creation
A Clear Path to Venture Creation Feasibility & de-risking Model options Ventures Coffeesai 01. Ideation and market Company Creation assessment Pluri CDMO 02. Partner collaboration for need validation Ever After Foods 03. Team recruitment Pluri Aesthetics 04. POC Funding and validation Joint-Venture
Slide 12: Pluri Establishes a Collaborative Network of Ventures
Pluri Establishes a Collaborative Network of Ventures IP Improvements Shared Shared Facilities and Network Know-how of Partners Accumulating Expertise
Slide 13: Joint Ventures
Joint Ventures
Slide 14: Growing the Future of Food with Cultivated Meat
Growing the Future of Food with Cultivated Meat Ever After Foods leverages Pluri’s cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry’s scalability challenges Environmental Ethical Consumer ● Less land an
Slide 15: Ever After Foods Milestones
Ever After Foods Milestones • Tnuva $7.5 million according to a $40 million pre- money valuation • Pluri granted exclusive global royalty-bearing license to use its IP and expertise
Slide 16: Company Creation
Company Creation
Slide 17: Reimagining Coffee Without Ecological Cost
Reimagining Coffee Without Ecological Cost Climate Change Land Shortage decrease reduce Price Instability Carbon Footprint risen water
Slide 18: A Consistent Methodology for Rapid, De-risked Venture Creation
A Consistent Methodology for Rapid, De-risked Venture Creation Oct.
Slide 19: The Coffeesai Solution uses 100% Real Coffee
The Coffeesai Solution uses 100% Real Coffee Drying Roasting Brewing
Slide 20: Out Licensing
Out Licensing
Slide 21: PLX-R18 for Acute Radiation Syndrome
PLX-R18 for Acute Radiation Syndrome Ongoing studies and collaborations Survival Rate • Studies conducted and funded by Significant increase vs placebo (p<0.0001) U.S. government (NIH, DoD) • $4.2 Million contract signed with the US NIAID1 • Collaboration agreement with Hemafund to enhance Ukraine’s
Slide 22: Pluri's Recent Achievements
Pluri’s Recent Achievements Collaborations €7.5 million Consolidated Launch of cell- with global Collaboration cash balance based coffee agriculture with Charite $27m (as of business corps Berlin September 30, 2024) $10m strategic Launch of US Government Cultivated meat Coffeesai to Developing Launc
Slide 23: Science in Service of Humanity
Science in Service of Humanity Pluri is a global leader in cell technology, aiming to deliver cell-based solutions with a goal to improve global well-being and drive sustainability in multiple sectors
Slide 24: Our Collaborative Network of Partnerships
Our Collaborative Network of Partnerships Regulatory Scientific Collaborations Funding and Partnering
Slide 25: Our Team
Our Team Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Efrat Livne-Hadass Orly Amiran Efrat Kaduri Chief Scientific Officer Chief Well
Slide 26: Thank You
THANK YOU. Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time. For further info: investor